Department of Pharmacology, B. J. Medical College, Ahmedabad, India.
Indian J Pharmacol. 2013 Mar-Apr;45(2):191-2. doi: 10.4103/0253-7613.108319.
Tenofovir was introduced as a second line drug for the treatment of human immunodeficiency virus (HIV) infection in India in December 2009. Although rare, renal toxicity is a recognized adverse drug reaction (ADR) of this drug, especially when administered with boosted lopinavir-ritonavir. In this case, an HIV positive patient receiving tenofovir based antiretroviral therapy (ART) for last 1 year developed albuminuria, glycosuria and hypophosphatemia. Renal function tests and random blood sugar were within normal limits. He was diagnosed as a case of tenofovir induced Fanconi syndrome. Tenofovir was discontinued and patient was prescribed an alternate regimen. Five months later clinical symptoms and renal functions returned to normal. A pharmacokinetic interaction between tenofovir and ritonavir may have resulted in the toxicity. A periodic monitoring of renal functions is desirable in patients on tenofovir based ART.
替诺福韦于 2009 年 12 月在印度被引入作为治疗人类免疫缺陷病毒（HIV）感染的二线药物。虽然罕见，但肾毒性是该药物公认的药物不良反应（ADR），尤其是与利托那韦增强洛匹那韦联合使用时。在本例中，一名接受替诺福韦为基础的抗逆转录病毒治疗（ART）已有 1 年的 HIV 阳性患者出现了蛋白尿、糖尿和低磷血症。肾功能检查和随机血糖均在正常范围内。他被诊断为替诺福韦诱导的范可尼综合征。停用了替诺福韦，并为患者开了替代方案。五个月后，临床症状和肾功能恢复正常。替诺福韦和利托那韦之间可能存在药代动力学相互作用，导致了这种毒性。在接受替诺福韦为基础的 ART 治疗的患者中，有必要定期监测肾功能。
